Cancer Discov. 2016 Dec;6(12):OF7. doi: 10.1158/2159-8290.CD-NB2016-126. Epub 2016 Oct 17.
The UK-based ProtecT trial reports that, after a median of 10 years of follow up, there is no significant difference in prostate cancer-specific mortality between active monitoring, surgery, and radiotherapy. However, the likelihood of developing metastases is more than twice as great with active monitoring compared with treatment.
英国的 ProtecT 试验报告称，中位随访 10 年后，主动监测、手术和放疗在前列腺癌特异性死亡率方面没有显著差异。然而，与治疗相比，主动监测发生转移的可能性要高出两倍多。
